We have previously shown that bile acids can activate the JNK pathway and down-regulate cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the neutral pathway of bile acid biosynthesis. In this study, the mechanism(s) by which deoxycholic acid (DCA) activates the JNK pathway were examined. FAS receptor (FAS-R) and acidic sphingomyelinase (ASM) deficient hepatocytes were resistant to DCA-induced activation of the JNK pathway. Activation of the JNK pathway (2 to 3-fold) in response to tumor necrosis factor-α (TNF-α) was similar in both wild-type and FAS-R -/-hepatocytes. In wild-type and FAS-R -/-hepatocytes, ceramide elevation was detected as early as 2 minutes and peaked at 10 minutes after DCA treatment. In contrast, ASM -/-hepatocytes were defective in DCA-induced ceramide generation. Treatment with DCA resulted in movement of FAS-R to the cell surface, which was blocked upon treatment with Brefeldin A. However, Brefeldin A failed to block DCA-mediated JNK activation in wildtype hepatocytes. DCA-induced JNK activation was independent of either the epidermal growth factor receptor (EGFR) activation or free radical generation. Addition of ASM to rat hepatocytes activated JNK and down-regulated CYP7A1 mRNA levels. In conclusion, these results show that DCA activates JNK and represses CYP7A1 mRNA levels in primary hepatocytes via an ASM/FAS-R-dependent mechanism which is independent of either the EGFR or free radical generation.
INTRODUCTION
Bile acids are steroid molecules that are synthesized from cholesterol in the liver. They function as important regulators of cholesterol metabolism in the hepatocyte by modulating the expression of genes encoding cholesterol degrading enzymes (bile acid biosynthetic enzymes) as well as cholesterol and phospholipid transport proteins (1, 2) . However, under certain pathophysiological conditions such as cholestasis, bile acids can promote cellular apoptosis and necrosis (3) (4) (5) . Bile acid structure appears to play an important role in the regulation of their various physiological functions in the cell (1) . Generally, hydrophobic bile acids such as lithocholic acid (LCA) (6, 7) , chenodeoxycholic acid (CDCA) (8, 9) and deoxycholic acid (DCA) (10) (11) (12) are more potent regulators of gene expression and promoters of liver injury than the more hydrophilic bile acids, such as ursodeoxycholic acid (UDCA) (7, 13) .
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(farnesoid X receptor) (22, 23) . Recent studies show that cholic acid feeding in both wild-type and SHP knock-out mice increases the levels of the active, phosphorylated JNK in vivo (19) .
Furthermore, it was shown that treatment of primary hepatocytes from wild-type and SHP -/-mice with the JNK inhibitor, SP600125, increases the basal expression levels of CYP7A1. However, additional studies in SHP knock-out mice also demonstrate the existence of other JNKdependent, but SHP-independent pathways regulating CYP7A1. It has been reported that bile acids can also feedback regulate CYP7A1 transcription through the nuclear receptor hepatocyte nuclear factor-4α (HNF-4α) (18) . Activation of the MEKK1/JNK pathway by bile acids has been shown to decrease the trans-activation potential of HNF-4α thereby down-regulating CYP7A1 transcription. Bile acids have also been shown to be able to activate liver macrophage cytokine production that can then initiate a cascade that activates JNK in the hepatocyte; a process which decreases the transcriptional activation of CYP7A1 (24) . More recently, the nuclear bile acid receptor FXR was shown to directly regulate the expression of fibroblast growth factor-19 (FGF-19), a secreted growth factor that signals through the receptor tyrosine kinase, FGFR-4 (fibroblast growth factor receptor-4) (25) . In turn, activated FGFR-4 repressed CYP7A1 gene expression via a JNK-dependent pathway. Collectively, the above studies clearly underscore the importance of the JNK signaling pathway in regulation of CYP7A1 gene expression by bile acids. However, the molecular events by which bile acids activate this pathway in hepatocytes have not yet been fully elucidated.
In other studies, we have shown that low concentrations of DCA cause activation of the Raf-1/MEK/ERK signaling cascade via activation of the epidermal growth factor receptor (EGFR) (10, 16) . Activation of this pathway was found to be a protective response of primary hepatocytes to DCA, as a blockade of DCA induced ERK1/2 activation dramatically increased apoptosis ~8-fold within 6 h of exposure. Apoptosis was dependent on bile acid-induced, ligand independent activation of the FAS death receptor (FAS-R; CD95). Studies by other groups indicate that toxic bile acids can activate FAS-R by directly increasing its cell surface density via induction of FAS-R trafficking to the plasma membrane (7) (8) (9) . The increased density of cell surface FAS-R likely promotes its oligomerization, formation of a death-inducing signal complex (DISC), and subsequent induction of apoptosis. Both PKC and JNK have been implicated in FAS-R trafficking to the plasma membrane (7, 9) . However, PKC and JNK may have multiple targets in the apoptotic cascade. More recent studies have suggested that JNK signaling may have both pro-and anti-apoptosis signaling effects in hepatocytes (26) (27) (28) . Indeed, studies from our laboratory demonstrate that bile-acid-induced activation of the FAS receptor can generate opposing signals, receptor-induced JNK1 activation, resulting in cell death, and receptor-induced JNK2 activation, resulting in protection and metabolism regulation (12) .
Hence, depending upon the concentration, structure and conjugation state of the bile acid being presented to the hepatocyte, it can either initiate an apoptotic response or promote cell survival via an interaction of multiple signaling pathways and transcription factors.
Clustering or aggregation of cell surface receptor molecules upon ligand binding has been reported for a variety of receptors, including tumor necrosis factor (29) , insulin (30), epidermal growth factor (31), FAS (32) (33) (34) (35) , CD40 (36), L-selectin (37), immunoglobulin (38) , and T-cell receptor (39, 40) . These receptors are known to cluster in distinct cholesterol-and sphingolipidrich domains of the cell membrane, termed rafts (41) . Evidence suggests that membrane rafts are the specific sites for ceramide generation in response to various agonists and stress signals (42) .
Cellular ceramide is generated either by hydrolysis of sphingomyelin or by de novo biosynthesis (43) . Sphingomyelin hydrolysis can be catalyzed by at least three different sphingomyelinases:
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http://www.jbc.org/ Downloaded from acid (ASM), neutral (NSM), and alkaline sphingomyelinases. The current model of FAS-R signaling suggests that engagement of FAS-R by its ligand or anti-Fas antibody results in translocation of ASM from an intracellular pool to the outer leaflet of the plasma membrane to hydrolyze sphingomyelin and release ceramide in membrane rafts (32, 34) . Local release of ceramide in these rafts results in the reorganization of rafts into larger platforms within which FAS-R aggregates and clusters. Clustering of FAS-R appears to facilitate oligomerization of downstream FAS effectors, bringing it in close contact with other signaling molecules and/or excluding inhibitory signaling mechanisms, all of which promote FAS-mediated signaling.
Modification of rafts by ceramide, generated via activation of ASM, has also been shown to play an important role in non-apoptotic signaling pathways that require clustering of specific receptors (44) . Furthermore, rafts altered by ASM activation may be involved in non-receptormediated signaling. Activation of the FAS-and TNF-receptor by stress stimuli (irradiation, heat shock or UV light) has been observed to occur independently of the FAS-ligand or TNF, respectively (44) (45) (46) (47) . It has been proposed that some stress stimuli might alter the conformation of FAS-R or change the composition of rafts permitting trapping of unliganded FAS-R molecules. This may result in low level receptor activation sufficient to initiate intracellular signaling.
In the present studies, we show that expression of the FAS receptor in primary hepatocytes is critically involved in activation of the JNK pathway by bile acids. Moreover, ceramide generated by ASM seems to be a key player in JNK activation in hepatocytes. These data provide a mechanistic basis for the activation of the JNK pathway by physiologic concentrations of bile acids via activation of ASM and generation of ceramide. (Table I) . Quantitation of CYP7A1 mRNA -Total RNA was prepared from cultured hepatocytes using guanidium thiocyanate CsCl centrifugation. CYP7A1 mRNA levels were determined by RNase protection assay (RPA) as described previously (14) . Rat cyclophilin mRNA was used as an internal control.
EXPERIMENTAL PROCEDURES

Measurement of Endogenous Ceramide
Statistical Analyses  Data were analyzed by Students t-Test. Level of significance was set at P
RESULTS
Previous studies from our laboratory have shown that bile acids at physiological concentrations (5-50 µM) significantly and rapidly increased JNK activity in primary rat hepatocytes (17) .
Recent studies from our laboratory and others have suggested that toxic bile acids and bile acids at patho-physiological concentrations (> 150 µM) activate the FAS receptor independently of its ligand, resulting in hepatocyte apoptosis (7) (8) (9) (10) 21) . In many cell types, activation of the FAS receptor has been reported to trigger activation of the JNK pathway (51) . We have recently
shown that in JNK1 -/-and JNK2 -/-hepatocytes, treatment with DCA leads to JNK pathway activation, with DCA-induced JNK1 activation, resulting in cell death, and DCA-induced JNK2 activation, resulting in protection (12) . To investigate whether the FAS receptor is involved in activation of the JNK pathway by bile acids, hepatocytes isolated from wild-type (C57BL/6) and FAS-R -/-(lpr) mice were treated with 50 µM DCA. As previously reported, JNK was activated in wild-type hepatocytes following DCA treatment (Fig. 1A) . However, hepatocytes from FAS-R -/-mice failed to activate JNK in response to DCA. As a positive control, tumor necrosis factor-α (TNF-α) activated JNK similarly (2-to 3-fold) in both wild-type and FAS-R -/-hepatocytes (Fig.   1B) .
We have previously shown that DCA can also activate the ERK pathway via activation of the EGF receptor (10, 16) . Activation of EGFR, as determined by increased receptor tyrosine phosphorylation, was found to be dependent upon reactive oxygen species mediated inhibition of anti-EGFR protein tyrosine phosphatase activity. A recent report in literature suggests that bile acid-induced EGFR activation can also activate the FAS-R via increased EGFR-mediated FAS-R tyrosine phosphorylation, which triggers FAS-R membrane targeting and DISC formation (52) .
To determine whether activation of EGFR by DCA also plays a role in activation of the JNK pathway, we individually pretreated primary rat hepatocytes with 5 µM AG1478, a specific tyrphostin inhibitor of EGFR, 100 µM genistein, a non specific tyrosine kinase inhibitor, or the antioxidant, N-acetyl cysteine (NAC; 20 mM). Activation of the JNK pathway by DCA was not blocked in the presence of AG1478, genistein or NAC, suggesting that DCA-mediated JNK activation is independent of the activation of the EGF receptor ( Fig. 2A and B) . Moreover, activation of the ERK pathway by DCA (50 µM) was similar in both wild-type and FAS-R -/-mice (180% and 195% of untreated controls respectively).
Because recent studies in literature suggest that ASM-mediated ceramide generation is critically involved in FAS-R signaling by promoting FAS-R clustering in ceramide-enriched membrane rafts (32, 34), we examined the ability of DCA to enhance ceramide levels in wildtype, FAS-R -/-and ASM -/-hepatocytes. Cells were treated with 50 µM DCA over a period of 30 min and ceramide levels assayed by the DAG kinase enzymatic method. Ceramide levels increased to 163 ± 22% of control levels (p < 0.05) after 2 min in wild-type (sv129 x C57BL/6) hepatocytes and remained elevated for at least 20 min (Fig. 3) . However, hepatocytes isolated from ASM -/-mice failed to generate ceramide in response to treatment with DCA. In contrast,
hepatocytes from both wild-type (C57BL/6) and FAS-R -/-mice responded by rapid ceramide elevation to DCA treatment (Fig. 4) . Addition of exogenous sphingomyelinase to generate ceramide and hence by-passing FAS-R in FAS-R -/-cells, failed to activate JNK (Fig. 5A ). These data suggest that the machinery for ceramide generation is intact in FAS-R -/-hepatocytes, and it is the lack of the FAS receptor per se that is responsible for the inability of these cells to activate JNK in response to bile acids or exogenous ceramide addition. Moreover, these studies support the notion that ceramide generated via activation of ASM by bile acids seems to play a key role in FAS-R-mediated JNK activation in mouse hepatocytes.
To further test this hypothesis, we determined activation of the JNK pathway by DCA in hepatocytes isolated from wild-type (sv129 x C57BL/6) and ASM -/-mice. We observed that genomic deletion of the alleles to express ASM prevented DCA-mediated JNK activation, and that addition of bacterial sphingomyelinase (NSM) to generate ceramide or C 2 -ceramide addition, rescued the phenotype (Fig. 5B and data not shown) . Table II) . ASM -/-hepatocytes failed to translocate FAS-R onto the cell surface after stimulation with DCA ( Fig. 6B and Table II) . Hepatocytes from both wild-type and ASM -/-mice displayed equal amounts of total cell FAS-R as measured in permeablized cells (data not shown).
During bile acid-induced hepatocyte apoptosis, a Golgi-associated and microtubuledependent pathway has been implicated in FAS-R trafficking to the plasma membrane (9) . Thus, we pre-incubated primary hepatocytes for 30 min with brefeldin A, a drug that blocks Golgidependent protein secretion (60). Brefeldin A prevented surface translocation of FAS-R upon stimulation with DCA in wild-type hepatocytes ( Fig. 6A and Table II) . However, no effect on DCA-induced JNK activation was observed when primary mouse hepatocytes were pre-treated with brefeldin A (Fig. 7A and B) . These studies argue that although bile acids can promote FAS-R trafficking to the plasma membrane, FAS-R movement to this location is not required to activate JNK in primary hepatocytes.
Bile acid-induced activation of the JNK pathway in primary rat hepatocytes downregulates expression of the CYP7A1 gene (17) . Our data supports a pivotal role of ASM/ceramide in FAS-R-mediated JNK activation. Hence, we determined whether addition of exogenous ASM (human placental sphingomyelinase) would also activate JNK and downregulate CYP7A1. Because the CYP7A1 gene is turned off in mouse hepatocytes in culture (unpublished observation), we performed these studies in primary cultures of rat hepatocytes.
When rat hepatocytes were treated with 1U/ml of ASM, JNK activity was strongly induced (Fig.   8 ). Activation of JNK by exogenous ASM was comparable to that for activation by DCA. As expected, addition of either ASM or DCA resulted in a ~50% decrease in CYP7A1 mRNA levels within 6 h (Fig. 9) .
DISCUSSION
The present studies were designed to provide mechanistic information by which bile acids activate the JNK pathway in primary hepatocytes. The results demonstrate that (i) FAS-R is required for DCA-mediated JNK activation, which is independent of EGFR signaling and free radicals; (ii) FAS receptor trafficking to the plasma membrane does not play a role in JNK activation by DCA; and (iii) ceramide generation via ASM is an essential pre-requisite for FAS-R and JNK activation, and down-regulation of CYP7A1 gene expression. These data suggest that DCA activates ASM in primary hepatocytes. The increase in ceramide levels then causes activation of the FAS receptor predominantly located internally, resulting in JNK activation and CYP7A1 mRNA down-regulation. Hence, the molecular ordering of events according to the present data is: DCA → ASM activation → ceramide generation → FAS-R activation → JNK activation → CYP7A1 transcriptional repression.
The role of FAS-R in programmed cell death (apoptosis) has been well documented and hepatocyte apoptosis is a common pathologic feature of cholestatic liver diseases. Bile acid induced apoptosis has been linked to the activation of the FAS receptor, and more recently also to the TRAIL-R2/DR5 death receptors (7) (8) (9) (10) 61) . Exposure of hepatocytes to TNF-α also can elicit an apoptotic response (27, 28) . Data from our laboratory and others has shown that apoptosis in hepatocytes, mediated by DCA and conjugated bile acids (GCDCA, TCDCA, and TLCS), is dependent upon ligand-independent signaling from the FAS receptor (7) (8) (9) (10) . We have recently shown that DCA-induced JNK1 signaling was cytotoxic, whereas DCA-induced JNK2 signaling was cytoprotective in primary hepatocytes (12) . In this manuscript, we show that DCA can activate the JNK pathway in wild-type but not FAS-R -/-hepatocytes. Since TNF-α activated JNK similarly in both wild-type and FAS-R -/-hepatocytes, this suggests that the mechanism of activation of the JNK pathway by bile acids is different from its activation by inflammatory cytokines in primary hepatocytes. Recently, it was shown that bile acid-mediated activation of the FAS receptor was dependent upon reactive oxygen species-mediated activation of the EGF receptor (52) . However, our data shows that neither genistein, AG1478 nor NAC blocks DCAmediated JNK activation in primary rat hepatocytes, arguing that bile acid-mediated FAS-R activation does not require prior phosphorylation by the EGFR. Activation of JNK by DCA significantly repressed CYP7A1 mRNA levels. This is similar to our previous data where we found that bile acid-induced JNK activation down-regulated CYP7A1 gene expression in the absence of cytotoxicity (17) . Thus, the present data identify CYP7A1 as a new JNK-regulated downstream target of DCA-activated FAS-R in primary hepatocytes.
Our notion of activation of JNK by FAS receptor is supported by previous studies showing that Jo2 or FAS-L can stimulate JNK activation (51). While death receptor-mediated
JNK activation is often associated with the induction of apoptosis, several studies have shown that inhibition of JNK has either no effect or a weak attenuating effect on death receptor- Ceramide generation has been shown to be essential for FAS-R receptor clustering, an event required for optimal FAS-R signaling in some cells (32) (33) (34) . Moreover, ceramide can also serve as a second messenger, leading to induction of the JNK pathway (43) . In our system, the ability of DCA to increase ceramide levels in both wild-type and FAS-R -/-hepatocytes and the failure of exogenous ceramide to activate JNK in FAS-R -/-cells suggests a hierarchical organization of ceramide and the FAS pathway, with sphingomyelinase-mediated ceramide generation being upstream of FAS-R/JNK signaling. A recent report has suggested that ligand-bound FAS-R and ceramide constitute the minimal requirements for FAS-R clustering (34) . However, our data and the findings of others show that bile acids can activate the FAS-R independent of the FAS-ligand (7) (8) (9) (10) 21) . It is possible that bile acids could potentially interact with FAS-R and alter its conformation and/or change the composition of lipid rafts via promoting ASM translocation to the cell surface, thereby permitting trapping of unliganded FAS-R molecules. This may then result in low level receptor activation sufficient to initiate intracellular signaling. However, additional studies will be needed to answer these questions.
In summary, our data provide evidence for a novel function of a death receptor i.e.
regulation of a gene, CYP7A1, involved in cholesterol metabolism (bile acid biosynthesis). We show that DCA activates JNK and down-regulates CYP7A1 in primary hepatocytes via an ASM/FAS-R/JNK-dependent mechanism which is independent of either the EGFR or free radical generation.
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